Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 18/20 | 0.49 |
| ▸ | CNR1 | P21554 | 14/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7879429 | 0.86 | LMNA (0.47) | CNR2CNR1LMNAHSD17B10 | |
| SCHEMBL2108648 | 0.80 | HTT (0.48) | CNR2CNR1LMNAHSD17B10AR | |
| SCHEMBL2108184 | 0.80 | CYP3A4 (0.62) | CNR1LMNAAR | |
| SCHEMBL2108030 | 0.80 | CYP3A4 (0.54) | CNR2CNR1 | |
| SCHEMBL4074135 | 0.80 | CYP3A4 (0.62) | CNR2CNR1LMNA | |
| SCHEMBL10492948 | 0.79 | NR5A1 (0.53) | CNR2CNR1 | |
| SCHEMBL1592413 | 0.78 | CYP3A4 (0.53) | CNR2CNR1 | |
| SCHEMBL10513794 | 0.77 | NR5A1 (0.56) | CNR2CNR1 | |
| SCHEMBL11142778 | 0.77 | CNR2 (0.44) | CNR2CNR1 | |
| SCHEMBL9636030 | 0.77 | MAPK1 (0.55) | CNR2CNR1LMNAHSD17B10AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158088-B2 | Extractant compositions for co-extracting cesium and strontium, a method of separating cesium and strontium from an aqueous feed, and calixarene compounds | BATTELLE ENERGY ALLIANCE, LLC (US) | 2012-04-17 | — | — | US | claimed |
| US-20100116749-A1 | EXTRACTANT COMPOSITIONS FOR CO EXTRACTING CESIUM AND STRONTIUM, A METHOD OF SEPARATING CESIUM AND STRONTIUM FROM AN AQUEOUS FEED, CALIXARENE COMPOUNDS, AND AN ALCOHOL MODIFIER | UT-BATTELLE, LLC | 2010-05-13 | — | — | US | claimed |
| US-8270554-B2 | Methods of producing cesium-131 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100296616-A1 | METHODS OF PRODUCING CESIUM-131 | BATTELLE ENERGY ALLIANCE, LLC (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100116749-A1 | EXTRACTANT COMPOSITIONS FOR CO EXTRACTING CESIUM AND STRONTIUM, A METHOD OF SEPARATING CESIUM AND STRONTIUM FROM AN AQUEOUS FEED, CALIXARENE COMPOUNDS, AND AN ALCOHOL MODIFIER | CANX, CBX6, CALD1 | CNR2 303/4885CNR1 118/4885LMNA 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.